Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.49 USD
Change Today -0.0101 / -2.02%
Volume 24.5K
CRXM On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

taxus cardium pharmaceutical (CRXM) Snapshot

Open
$0.50
Previous Close
$0.50
Day High
$0.50
Day Low
$0.41
52 Week High
06/24/14 - $0.78
52 Week Low
02/13/15 - $0.07
Market Cap
6.3M
Average Volume 10 Days
20.5K
EPS TTM
$-0.45
Shares Outstanding
12.8M
EX-Date
10/24/05
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAXUS CARDIUM PHARMACEUTICAL (CRXM)

Related News

No related news articles were found.

taxus cardium pharmaceutical (CRXM) Related Businessweek News

No Related Businessweek News Found

taxus cardium pharmaceutical (CRXM) Details

Taxus Cardium Pharmaceuticals Group Inc. operates as a development-stage regenerative medicine biotechnology company. It focuses on developing regenerative therapeutics designed to support the activation and growth of microvascular circulation to enhance perfusion of ischemic cardiac tissue as a potential treatment for heart disease; and granulation tissue as a treatment for chronic non-healing wounds. The company provides Excellagen, a topical gel for wound healing of diabetic foot ulcers, and other dermal wounds, as well as serves as a biologics delivery platform in the United States. It develops Generx, a lead Phase III clinical study product candidate for the treatment of patients with Cardiac Microvascular Insufficiency due to advanced coronary artery disease. In addition, the company develops LifeAgain, a medical analytics and social media-driven enabled e-commerce platform that is focused on developing, marketing, and direct sale of life insurance programs and other insurance products for individuals with prostate cancer. Taxus Cardium Pharmaceuticals Group Inc. has strategic collaborations with Shanxi Taxus Pharmaceuticals Co., Ltd. for the development of advanced regenerative medicine therapeutics products; and Orbsen Therapeutics Ltd. The company was formerly known as Cardium Therapeutics, Inc. and changed its name to Taxus Cardium Pharmaceuticals Group, Inc. in March 2014. Taxus Cardium Pharmaceuticals Group, Inc. was founded in 2003 and is headquartered in San Diego, California.

taxus cardium pharmaceutical (CRXM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $332.8K
Co-Founder, Chief Business Officer, Executive...
Total Annual Compensation: $309.0K
Chairman of Scientific Advisory Board and Chi...
Total Annual Compensation: $244.3K
Compensation as of Fiscal Year 2013.

taxus cardium pharmaceutical (CRXM) Key Developments

TaxuCardium Pharmaceuticals Group Inc. announced delayed 10-Q filing

On 05/18/2015, TaxuCardium Pharmaceuticals Group Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Taxus Cardium Pharmaceuticals Group Inc. Enters into Binding Term Sheet with Dr. Reddy’S Laboratories Ltd

Taxus Cardium Pharmaceuticals Group Inc. announced that it has entered into a binding term sheet with Dr. Reddy’s Laboratories Ltd. for an exclusive territorial license covering the co-development, marketing and sales of the Generx® [Ad5FGF-4] angiogenic microvascular gene therapy Phase 3 product candidate for patients with refractory angina, and myocardial ischemia due to cardiac microvascular insufficiency (CMI). The agreement initially covers certain territories and international markets, including Russia, the Commonwealth of Independent States (CIS), Venezuela, Vietnam and Myanmar, and provides the right of first refusal for Dr. Reddy’s Laboratories to negotiate additional exclusive license agreements to market and sell the Generx gene therapy product candidate in over 30 other countries in Latin America and the Association of Southeast Asian Nations. Angionetics Inc. is now responsible for the worldwide commercialization of the Generx gene therapy product candidate. Angionetics retains the full Generx commercialization rights for North America, Europe, Japan, China, the Middle East, and Africa. It is planned that Angionetics will advance forward as a company independent from Taxus Cardium and seek to externally finance the Generx U.S.-based FDA-cleared AWARE Phase 3 clinical study, the international ASPIRE Phase 3 clinical development program and additional U.S.-based and international clinical studies for other potential Generx medical indications. As an international co-development partner, Dr. Reddy’s Laboratories will assist with local country patient recruitment and relationship building with key opinion leaders to accelerate the Angionetics’ international Phase 3 ASPIRE clinical study. Positive safety and efficacy findings from the ASPIRE study were announced at the Annual 2014 Biotechnology Industry Organization Conference following completion of a protocol-specified interim data analysis. In addition, Dr. Reddy’s Laboratories will assist with product registrations and regulatory compliance with local country health authorities. The agreement provides economic support that will be used to advance the international Phase 3 clinical study, a cost sharing arrangement for a planned Phase 4 post-marketing clinical study (intended to expand product labeling), and volume-based royalties on net sales. Dr. Reddy’s Laboratories’ Russian-based business unit.

Dennis Mulroy Resigns as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group Inc on April 3, 2015

On April 3, 2015, Dennis Mulroy resigned as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group Inc. Mr. Mulroy resigned to pursue other opportunities and did not receive any severance payments under his employment agreement in connection with his departure. Mr. Mulroy's departure is not due to any dispute or disagreement with the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRXM:US $0.49 USD -0.0101

CRXM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CRXM.
View Industry Companies
 

Industry Analysis

CRXM

Industry Average

Valuation CRXM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAXUS CARDIUM PHARMACEUTICAL, please visit www.cardiumthx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.